Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonu

Details Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonu Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonu

1998-07-09

2000-03-28

Guzo, David

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

435 6, 435 911, 536 231, 536 245, C12Q 168, C07H 2104

Patent

active

060428465

ABSTRACT:
An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.

REFERENCES:
patent: 4480041 (1984-10-01), Myles et al.
patent: 4721612 (1988-01-01), Janoff et al.
patent: 4924624 (1990-05-01), Suhadolnik et al.
patent: 4950432 (1990-08-01), Mehta et al.
patent: 5030442 (1991-07-01), Uster et al.
patent: 5049388 (1991-09-01), Knight et al.
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5112962 (1992-05-01), Letsinger et al.
patent: 5135917 (1992-08-01), Burch
patent: 5178875 (1993-01-01), Lenk et al.
patent: 5188897 (1993-02-01), Suhadolnik et al.
patent: 5227170 (1993-07-01), Sullivan
patent: 5248671 (1993-09-01), Smith
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5271941 (1993-12-01), Cho-Chung
patent: 5279957 (1994-01-01), Gross
patent: 5320962 (1994-06-01), Stiles et al.
patent: 5324654 (1994-06-01), Bredesen
patent: 5417978 (1995-05-01), Tari et al.
patent: 5560923 (1996-10-01), Rahman et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5734033 (1998-03-01), Reed
patent: 5756122 (1998-05-01), Thierry et al.
patent: 5817811 (1998-10-01), Breipohl et al.
patent: 5855911 (1999-01-01), Tari et al.
patent: 5874553 (1999-02-01), Peyman et al.
patent: 5908635 (1999-06-01), Thierry
Gewirtz, et al., Facilitating oligonucleotide delivery: helping antisense deliver on its promise, Proc. Natl. Acad. Sci., vol. 93, pp. 3161-3163, Apr. 1996.
Branch, A good antisense molecule is hard to find, TIBS, vol. 23, pp. 45-50, Feb. 1998.
Bakhshi et al., "Cloning the Chromosomal Breakpoint of t(14;18) Human Lymphomas: Clustering around J.sub.H on Chromosome 14 and near a Transcriptional Unit on 18," Cell, 41:899, 1985.
Cotter et al., "Antisense oligonucleotides supress B-cell lymphoma growth in a SCID-hu mouse model." Oncogene, 9:3-49-3055, 1994.
Kramer et al., "Self-specific T lymphocyte lines as vehicles for gene therapy: myelin specific T cells carrying exogenous nerve growth factor gene (abstract)," J. Cell. Biochem., Suppl. o (17 Part E):215, 1993.
Thompson, C. B., "Apoptosis in the Pathogenesis and Treatment of Disease," Science, 267:1456-1462, 1995.
Tormo et al., "Antitumor activity of liposomal-bcl-2-antisense oligonucleotides in follicular lymphoma (abstract)," Proc. Am. Assoc. Cancer. Res., 37:1190, 1996.
Tsujimoto et. al, "The t(14;18) chromosome translocation involved in B-cell neoplasms result from mistakes in VDJ joining," Science, 229:1390, 1985.
Webb et al., "Extrathymic Tolerance of Mature T Cells: Clonal Eliminations as a Consequence of Immunity," Cell, 63:1249, 1990.
Williams, G.T., "Programmed Cell Death: Apoptosis and Oncogenesis," Cell, 65:1097-1098, 1991.
Zhang et al., "Gene therapy for the peripheral nervous system rat neuritogenic T cell line carry mouse nerve growth factor gene (abstract)," J. Cell. Biochem., Suppl. 0 (17 Part E):SZ-116, 1993.
Akhtar et al., "Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)," Nucleic Acids Research, 19(20):5551-5559, 1991.
Thierry et al., "Liposomal delivery as a new approach to transport antisense oligonucleotides," Gene Regulation, Biology of Antisense RNA and DNA, 1: 147-161, 1992.
Theirry et al., "Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotidesfor antisense activity," Nucleic Acids Research, 20(21):5691-5698, 1992.
Ropert et al., "Inhibition of the friend retrovirus by antisense oligonucleotdies encapsulated in liposomes:mechanism action," Pharmaceutical Research, 10(10):1427-1433,1993.
Tari et al., "Liposomal delivery of methylphosphonate antisense oligodeoxynucleotidesin chronic myelogenous leukemia," Blood, 84(2):601-607, 1994.
Akhtar et al., "Liposome delivery of antisense methylphosphonate and phosphorothioate oligonucleotides: A study with MLV, FATMLV, and LUV liposomes," Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 19:345-346, 1992.
Akhtar et al., "Release of antisense oligdeoxynucleotide analogues from liposomes: implications for cellular transport and drug delivery," 128th Meeting of British Pharmaceutical Conference 1991, United Kingdom, Sep. 10-13, 1991, J. Pharm. Pharmacol., 43 (Suppl.):Abstract24P, 1991.
Thierry et al., "Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides," Biochemical and Biophysical Research Communications, 190(3):952-960, 1993.
Citro et al., "Chemical modification of ligands for cell receptors to introduce foreign compounds into the cells," Colon & Rectum, 37(2):S127-S132, 1994.
Clarenc et al., "Delivery of antisense oligonucleotides by poly(l-lysine) conjugation and liposome encapsulation," Anti-Cancer Drug Design, 8:81-94, 1993.
Loke et al., "Delivery of c-mycantisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-mycprotein expression correlates with inhibition of cell growth and DNA synthesis," Current Topics in Microbiology and Immunology, Mechanisms in B-Cell Neoplasia, 141:282-289, 1988.
Stein et al., "Oligodeoxynucleotides as inhibitors of gene expression: A review," Cancer Research, 48(10):2635-2944, 1988.
Tsuchida et al., "Iron-ligand bonding properties of synthetic iron-porphyrin complexes wtih oxygen transporting ability in aqueous media," J. Chem. Soc. Dalton Transactions, 10:2455-2458, 1987.
Arad et al., "Use of reconstituted sendai virus envelopes for fusion-mediated microinjection of double-stranded RNA: Inihibition of protein synthesis in interferon-treated cells," Biochimica et Biophysica Acta, 859:88-94, 1986.
Agris et al., "Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleosidemethylposphonates," Biochemistry, 25:6268-6275, 1986.
Martiat et al., "Retrovirally transduced antisense sequences stably suppress P210.sup.BCR-ABL expression and inhibit the proliferation of BCR/ABL-containingcell lines," Blood, 81(2):502-509, 1993.
Taj et al., "Inhibition of P210.sup.BCR/ABL expression in K562 cells by electroporation with an Antisense oligonucleotide," Leukemia and Lymphoma, 3:201-208, 1990.
Szczylik et al., Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides,,Science,253:562-565, 1991.
Tidd et al., "Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonateoligonucleotide analogues," Anti-Cancer Drug Design, 3:117-127, 1988.
Tidd et al., "Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups," Be. J. Cancer, 60:343-350, 1989.
Moody et al., "Regiospecific inhibtion of DNA duplication by antisense phosphate-methylated oligodeoxynucleotides,"Nucleic Acids Research, 17(12):4769-4782, 1989. (Abstract).
Loke et al., "Delivery of c-mycantisense oligdeoxynucleotides hematopoietic cells in culture by liposome fusion: Specific reduction in c-mycprotein expression corelates with inhibtion of cell growth and DNA synthesis," Clinical Research, AFCR Immunology Abstract, 36(3):443A, 1988.
Vasanthakumar et al., "Modulation of drug resistance in a daunorubicin resistant subline with oligonucleosidemethylphosphonates,"Cancer Communications, 1(4):225-232, 1989.
Leonetti et al., "Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication," Proc. Natl. Acad. Sci. USA, 87:2448-2451, 1990.
Renneisen et al., "Inhbition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the envregion," The Journal of Biological Chemistry, 265(27):16337-16342, 1990.
Boiziau et al., "Modified oligonucleotides in rabbit

Affiliated with

Also associated with

Rating

Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonu does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonu will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1323846